Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus MONOCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus MONOCID.
CEFAZOLIN IN DEXTROSE vs MONOCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV every 8 hours. For serious infections, up to 2 g IV every 6 hours.
1 g intramuscularly or intravenously every 24 hours; for severe infections, 2 g every 24 hours.
None Documented
None Documented
1.8 hours in normal renal function. Prolonged to 12-24 hours in end-stage renal disease (CrCl <10 mL/min).
Terminal elimination half-life: 4-5 hours (prolonged to 12-24 hours in severe renal impairment; dosing adjustment recommended for CrCl <50 mL/min).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: minor (<1%). Fecal: negligible.
Renal: ~90% unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: ~5% (cefonicid undergoes minimal hepatic metabolism; ~4% excreted in feces as parent drug and metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic